EPS for Rhythm Pharmaceuticals, Inc. (RYTM) Expected At $-0.45 on June, 11

May 17, 2018 - By Irene Marshall

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)’s earnings report is anticipated by WallStreet on June, 11, Zacks reports. After $-0.41 earnings per share was published previous quarter, analysts now see negative EPS growth of 9.76 % for Rhythm Pharmaceuticals, Inc.. RYTM hit $30.78 during the last trading session after $0.94 change.Rhythm Pharmaceuticals, Inc. has 145,865 shares volume, 44.87% up from normal. RYTM is and has moved 0.00% since May 17, 2017. The stock underperformed the S&P 500 by 11.55%.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States.The firm is worth $847.00 million. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.Currently it has negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More recent Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news were published by Globenewswire.com, Nasdaq.com and Nasdaq.com. The first one has “Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results” as a title and was published on May 14, 2018. The next is “Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of …” on May 09, 2018. And last was published on May 09, 2018, called “Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference”.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.